Filter Results:
(2,378)
Show Results For
- All HBS Web
(3,292)
- People (7)
- News (425)
- Research (2,378)
- Events (1)
- Multimedia (5)
- Faculty Publications (1,960)
Show Results For
- All HBS Web
(3,292)
- People (7)
- News (425)
- Research (2,378)
- Events (1)
- Multimedia (5)
- Faculty Publications (1,960)
Sort by
- August 2009 (Revised April 2012)
- Case
Genzyme's CSR Dilemma: How to Play its HAND
By: Christopher A. Bartlett, Tarun Khanna and Prithwiraj Choudhury
Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should... View Details
Keywords: Global Strategy; Health Care and Treatment; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Research and Development; Biotechnology Industry
Bartlett, Christopher A., Tarun Khanna, and Prithwiraj Choudhury. "Genzyme's CSR Dilemma: How to Play its HAND." Harvard Business School Case 910-407, August 2009. (Revised April 2012.)
- 2014
- Working Paper
Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms
By: Prithwiraj Choudhury and Tarun Khanna
Since the 1990s, several Western firms have filed patents based on medicinal herbs from emerging markets, evoking protests from local stakeholders against 'bio-piracy'. We explore conditions under which firms and local stakeholders share rents from such patents. Our... View Details
Keywords: Rents From New Technology; Local Stakeholders; Herbal Patents; QCA; Fuzzy Set Analysis; Qualitative Case Studies; Plant-Based Agribusiness; Patents; Emerging Markets; Health Care and Treatment; Business and Stakeholder Relations; Cross-Cultural and Cross-Border Issues; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry
Choudhury, Prithwiraj, and Tarun Khanna. "Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms." Harvard Business School Working Paper, No. 14-081, February 2014.
- March 2023
- Teaching Note
VideaHealth: Building the AI Factory
By: Karim R. Lakhani
Teaching Note for HBS Case No. 621-021. The case “VideaHealth: Building the AI Factory” examines the creation of dental startup VideaHealth (Videa) and the development of its artificial intelligence (AI)-led business strategy through the eyes of founder and CEO Florian... View Details
- October 2014 (Revised July 2016)
- Supplement
Gilead: Hepatitis C Access Strategy (B)
While the "Gilead: Hepatitis-C Access Strategy (A)" case (HBS No. 515-025) poses questions on what the company should do with respect to hard-hit countries like Egypt and India, the (B) case provides the answer. In both cases, the company chose to pursue a proactive... View Details
Rangan, V. Kasturi. "Gilead: Hepatitis C Access Strategy (B)." Harvard Business School Supplement 515-044, October 2014. (Revised July 2016.)
- April 1995 (Revised August 1995)
- Supplement
Empire Blue Cross and Blue Shield (C)
By: Regina E. Herzlinger and Ramona Hilgenkamp
Supplements the (A) case. View Details
Herzlinger, Regina E., and Ramona Hilgenkamp. "Empire Blue Cross and Blue Shield (C)." Harvard Business School Supplement 195-218, April 1995. (Revised August 1995.)
- May 1993
- Case
Alexander Hospital Gift Shoppe
Herzlinger, Regina E. "Alexander Hospital Gift Shoppe." Harvard Business School Case 193-117, May 1993.
- April 2011
- Supplement
Roche's Acquisition of Genentech (CW)
By: Bo Becker
Spreadsheet for case 210040. View Details
- December 2010
- Teaching Note
Urban Water Partners (TN) (A) and (B)
By: Karthik Ramanna and George Serafeim
Teaching Note for 111016 and 111029. View Details
- August 2010 (Revised January 2013)
- Supplement
Urban Water Partners (B)
By: Karthik Ramanna, George Serafeim and Aldo Sesia
The case explores a new business venture to bring clean water to residents of Dar es Salaam, Tanzania, who otherwise cannot afford it. Management has enough money to get their company through August 2010, but needs more capital thereafter. An HBS alumnus is interested... View Details
Keywords: Human Needs; Accrual Accounting; Financial Statements; Health Industry; Health Industry; Dar es Salaam
Ramanna, Karthik, George Serafeim, and Aldo Sesia. "Urban Water Partners (B)." Harvard Business School Supplement 111-029, August 2010. (Revised January 2013.)
- November 2007
- Class Lecture
The Baby Business (FSS)
By: Debora L. Spar
In vitro fertilization and genetic screening are possible with the advent of biotechnology. International adoptions, surrogacy, and other approaches to family planning are on the rise. But few rules govern these measures, medical costs can be prohibitive, and... View Details
Keywords: Governing Rules, Regulations, and Reforms; Policy; Demand and Consumers; Business and Government Relations; Business and Stakeholder Relations; Genetics; Societal Protocols; Commercialization; Biotechnology Industry; Biotechnology Industry
Spar, Debora L. "The Baby Business (FSS)." Harvard Business School Class Lecture 708-701, November 2007.
- May 1992
- Teaching Note
RU 486 (A) and (B), Teaching Note
Teaching Note for (9-391-050) and (9-391-051). View Details
- October 1990 (Revised April 1991)
- Case
RU 486 (A)
Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details
Keywords: Judgments; Ethics; Product Launch; Negotiation; Outcome or Result; Performance; Business and Government Relations; Health Industry; Health Industry; France; Germany; United States
Badaracco, Joseph L., Jr. "RU 486 (A)." Harvard Business School Case 391-050, October 1990. (Revised April 1991.)
- 15 Sep 2008
- Research & Ideas
The Coming Transformation of Social Enterprise
lower the better, with the logic being that more money can then go to actual programs. So an organization might report, "We spend 6 percent on fundraising, whereas the industry average is 12 to 14 percent." That's typical, but... View Details
Keywords: by Roger Thompson
- 14 Feb 2012
- First Look
First Look: February 14
individuals bring well-articulated preexisting preferences to such decisions. Understanding beliefs and attitudes motivating these preferences can assist physicians in helping parents make informed decisions consistent with their values. Consumer-Driven View Details
Keywords: Carmen Nobel
- 02 Dec 2009
- What Do You Think?
Should Immigration Policies Be More Welcoming to Low-Skilled Workers?
of cost shifting." J. Boxer points out that "there's a high cost to cheap labor, and that cost (free education, free health care, etc.) is passed on to the state and the taxpayer, generally." Eloton Fowler said, "Our... View Details
Keywords: by Jim Heskett
- July 2020
- Technical Note
Digital Natives Growing Without a Sales Force
By: Das Narayandas, Michael Norris and Amram Migdal
This brief case describes the rise of so-called digital natives (also called born-in-digital) in the 2000s and 2010s that successfully grew without a sales force. The case highlights the emergence of business-to-business Internet and cloud-based companies and their... View Details
Keywords: Government Administration; Crisis Management; Health; Health Pandemics; Innovation and Invention; Innovation Leadership; Innovation Strategy; Technological Innovation; Social Issues; Information Technology; Mobile and Wireless Technology; Applications and Software; Technology Adoption; Information Technology Industry; Australia; North and Central America; United States; Illinois; Chicago; California; San Francisco
Narayandas, Das, Michael Norris, and Amram Migdal. "Digital Natives Growing Without a Sales Force." Harvard Business School Technical Note 521-019, July 2020.
- 2024
- Article
Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway
By: Mateo Aboy, Cristina Crespo and Ariel Stern
Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Technology Adoption; Technological Innovation; Safety; Medical Devices and Supplies Industry; United States
Aboy, Mateo, Cristina Crespo, and Ariel Stern. "Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway." Art. 29. npj Digital Medicine 7 (2024).
- Summer 2020
- Article
Is It Time to Rethink Globalized Supply Chains?: The COVID-19 Pandemic Should Be a Wake-up Call for Managers and Prompt Them to Consider Actions That Will Improve Their Resilience to Future Shocks
By: Willy C. Shih
The COVID-19 pandemic has exposed the complex interdependencies of globalized supply chains. While these global multistage production networks had spread during a relatively benign environment of falling trade barriers and increasing interdependencies among countries,... View Details
Keywords: Supply Chains; Pandemic; Resilience; Supply Chain Management; Supply Chain; Global Range; Health Pandemics; Disruption; System Shocks; Crisis Management; Manufacturing Industry; United States; Asia; Europe; China
Shih, Willy C. "Is It Time to Rethink Globalized Supply Chains? The COVID-19 Pandemic Should Be a Wake-up Call for Managers and Prompt Them to Consider Actions That Will Improve Their Resilience to Future Shocks." MIT Sloan Management Review 61, no. 4 (Summer 2020): 16–18.
- August 2008 (Revised May 2009)
- Background Note
Note on Generic Drugs in the European Union
By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details